Drugs / HBV-MPL vaccine 208129
HBV-MPL vaccine 208129
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00699231 | Feb → Dec 1992 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00697853 | Nov 1998 → Jul 1999 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00697125 | Jun 1993 → Jul 1994 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT00697866 | Aug 2000 → Feb 2001 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00697554 | Jan 2000 → May 2002 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00698061 | Nov 1999 → Sep 2000 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00696917 | Apr 1999 → Feb 2000 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00697749 | Apr 1999 → Jan 2000 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00697216 | Mar 1997 → Mar 1999 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBV-MPL vaccine 208129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00697866 ↗ |
| Known as | adjuvanted HBV-MPL vaccine | “Subjects who had not responded to previous hepatitis B vaccination were vaccinated with either the adjuvanted HBV-MPL vaccine or Engerix™-B vaccine according to a three-dose...” NCT00698061 ↗ |
| Known as | HBV-MPL vaccine | “This study evaluates the safety and immunogenicity of the candidate HBV-MPL vaccine administered to healthy adults aged from 15 to 40 years, according to a 0, 6- month...” NCT00697216 ↗ |
| Known as | MPL-Adjuvanted Recombinant Hepatitis B Vaccine | “Study to Evaluate the Immunogenicity, Reactogenicity and Safety of GSK Biologicals' (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine...” NCT00699231 ↗ |
| Modality | Vaccine | “HBV-MPL vaccine 208129” NCT00696917 ↗ |
| Route | Intramuscular | “2-dose intramuscular injection 3 different vaccine lots” NCT00696917 ↗ |